fashion -WSS

fashion

author：entertainment 2025-09-30 20:18:04 - browse：82

inflamed intestine on a dark blue background — biotech coverage from STAT — Adobe

What happens after you close a nearly $11 billion acquisition?

Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was a brief vacation. But within weeks of the company’s acquisition by Merck closing last June, he was thinking about ideas for the future.

Investors were floating ideas by him. McKenna discussed possibilities with his teenagers and Prometheus’ chief scientific officer. This “summer of discovery,” as McKenna called it, brought him back to the immune system. Prometheus and some other companies have been able to capitalize on creating treatments for conditions like inflammatory bowel disease and psoriasis, while arthritis medications like Humira have brought in billions of dollars in sales. But the field hadn’t quite received the same attention as missions to cure cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： UnitedHealth’s Optum accused of antitrust violations in California

explore

WSS

30 years of 'Listening to Prozac'

Long Covid research funding gets a major boost from NIH

Juul documents reveal insider tactics on political lobbying

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Mayo Clinic plans $5B tech

Eli Lilly reports tirzepatide MASH success during Q4 earnings

entertainment

fashion

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Ebola vaccine can save some who are already sick, per new study

Medicare details structure of new drug price negotiation program

Flagship Pioneering launches a new biotech in two countries

Sports medicine is finally prioritizing gender equality

Abbott's new heart device gets FDA advisory panel nod

Medicare details structure of new drug price negotiation program

Will the market for weight loss drugs really reach $100 billion?

After affirmative action ruling, medical educators look to 'holistic review'

Long Covid research funding gets a major boost from NIH

explore

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

ReNAgade cuts staff seven months after raising $300 million

Study gives hint on South Asians’ higher risk of cardiovascular disease

Despite FDA concern, risk that CAR

Bernie Sanders gets little from pharma CEOs on drug prices

AMAs digital advisors table RPM coding reform proposal, again

explore

explore

hotspot

leisure time